[Staphylococcal infection in the newborn: teicoplanin therapy].
Infections caused by Gram-positive bacteria, particularly in neonatal patients, have increased dramatically over the past 10 years. In the present study 19 newborns (7 at term, 12 preterm) with proven staphylococcal infection were treated with teicoplanin, after a previous ineffective antibiotic treatment (amikacin+oxacillin or third-generation cephalosporin). Bacterial eradication and clinical cure were achieved in all neonates. No adverse events related to the drug occurred. No significant change was observed in serial biochemical and hematological tests. Our results suggest that teicoplanin is highly effective and safe in neonatal staphylococcal infections.
Fanos
V
V
Clinica Pediatrica, Università di Verona, Italia.
Khoory
B J
BJ
Danieli
D
D
Padovani
E M
EM
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008826:Microbial Sensitivity Tests; D012189:Retrospective Studies; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013210:Staphylococcus / Q000187:drug effects / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification; D013212:Staphylococcus epidermidis / Q000187:drug effects / Q000302:isolation & purification; D017334:Teicoplanin / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D017334:Teicoplanin
Sepsi da stafilococco nel neonato: terapia con teicoplanina.